May 27, 2020Journal of Clinical Oncology371 citationsOpen Access

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Key points are not available for this paper at this time.

Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

Cite This Study